Your browser doesn't support javascript.
loading
Seleno-vs. thioether triazine derivatives in search for new anticancer agents overcoming multidrug resistance in lymphoma.
Ali, Wesam; Garbo, Sabrina; Kincses, Annamária; Nové, Márta; Spengler, Gabriella; Di Bello, Elisabetta; Honkisz-Orzechowska, Ewelina; Karcz, Tadeusz; Szymanska, Ewa; Zeslawska, Ewa; Starek, Malgorzata; Dabrowska, Monika; Nitek, Wojciech; Kucwaj-Brysz, Katarzyna; Pyka, Patryk; Fioravanti, Rossella; Jacob, Claus; Battistelli, Cecilia; Zwergel, Clemens; Handzlik, Jadwiga.
Afiliação
  • Ali W; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland; Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbruecken, Germany.
  • Garbo S; Istituto Pasteur Italia, Fondazione Cenci-Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
  • Kincses A; Institute of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, 6725, Szeged, Hungary.
  • Nové M; Institute of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, 6725, Szeged, Hungary.
  • Spengler G; Institute of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, 6725, Szeged, Hungary.
  • Di Bello E; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
  • Honkisz-Orzechowska E; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Karcz T; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Szymanska E; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Zeslawska E; Institute of Biology, Pedagogical University of Krakow, Podchorazych 2, 30-084, Kraków, Poland.
  • Starek M; Department of Inorganic Chemistry, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Dabrowska M; Department of Inorganic Chemistry, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Nitek W; Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Kraków, Poland.
  • Kucwaj-Brysz K; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Pyka P; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Fioravanti R; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
  • Jacob C; Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbruecken, Germany.
  • Battistelli C; Istituto Pasteur Italia, Fondazione Cenci-Bolognetti, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. Electronic address: cecilia.battistelli@uniroma1.it.
  • Zwergel C; Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbruecken, Germany; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy. Electronic address: clemens.zwergel@uniroma1.it.
  • Handzlik J; Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9, 30-688, Kraków, Poland. Electronic address: j.handzlik@uj.edu.pl.
Eur J Med Chem ; 243: 114761, 2022 Dec 05.
Article em En | MEDLINE | ID: mdl-36179403
ABSTRACT
Lymphomas are still difficult to treat even with modern therapies as, among others, multidrug resistance (MDR) is often counteracting a successful cancer therapy. P-gp/ABC-transporters are well-known for their crucial role in the main tumour MDR mechanism, eliminating drugs and cytotoxic substances from the cancer cell by efflux, and their modulators are promising for innovative therapy, but none has been approved in the pharmaceutical market yet. Herein, we have designed, synthesised and analysed 30 novel seleno- and thioether 1,3,5-triazine derivatives conducting comprehensive studies to evaluate their potential application in human JURKAT lymphoma cells. Among the new compounds, four (11, 12, 13 and 23) were much more effective than the reference inhibitor verapamil, being potent ABCB1 inhibitors already at 2 µM, while 5 and 15 showed very potent ABCB1 inhibitory activity only at 20 µM. Results of P-gp ATPase assays, supported with docking studies, indicated the competitive substrate mode of modulating action for 15, while ABCB1, ABCC1 and ABCG2 genes expression induction by 15 with q-PCR was confirmed. All compounds were evaluated for their cytotoxic and antiproliferative properties in both sensitive (PAR) and resistant (MDR) mouse T-lymphoma cell lines, and compound 15, also considering its promising ABCB1 inhibition properties, was revealed to be the best compound in terms of its cytotoxic effect (IC50 16.73 µM) as well as concerning the antiproliferative effect (IC50 5.35 µM) in MDR cells. Regarding the mechanistic studies looking at the cell cycle, the thioether 15 and selenium derivatives 26 and 29 were significantly effective in the regulation of cell cycle-related genes alone or in co-treatment with doxorubicin counteracting Cyclin D1 and E1 expression and increasing p53 and p21 levels, shedding first light on their mechanism of action. In summary, we explored the chemical space of seleno- and thioether 1,3,5-triazine derivatives with interesting activity against lymphoma. Especially compound 15 is worthy of being studied deeper to evaluate its precise mode of action further as well it can be improved regarding its potency and drug-likeness.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Eur J Med Chem Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha